<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="2374">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on December 16, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05130255</url>
  </required_header>
  <id_info>
    <org_study_id>1001</org_study_id>
    <nct_id>NCT05130255</nct_id>
  </id_info>
  <brief_title>GD2-SADA:177Lu-DOTA Complex in Patients With Solid Tumors Known to Express GD2</brief_title>
  <official_title>Phase 1 Trial With GD2-SADA:177Lu-DOTA Complex in Patients With Recurrent or Refractory Metastatic Solid Tumors Known to Express GD2, Including Small Cell Lung Cancer, Sarcoma and Malignant Melanoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Y-mAbs Therapeutics</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Y-mAbs Therapeutics</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Patients with Small Cell Lung Cancer, Sarcoma and Malignant Melanoma will be treated with&#xD;
      GD2-SADA:177Lu-DOTA complex(The IMP is a two-step radioimmunotherapy, delivered as two&#xD;
      separate products GD2-SADA and 177Lu-DOTA) to assess safety and tolerability&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A phase 1 dose-escalation single-arm, open-label, non-randomized, multi-center trial of the&#xD;
      safety and tolerability of GD2-SADA:177Lu-DOTA complex in GD2 expressing solid tumors.&#xD;
&#xD;
      The trial is planned as a Phase 1 trial with three parts, A, B and C. Escalation in this&#xD;
      trial will be based on a classical 3+3 trial design.&#xD;
&#xD;
      Part A is a GD2-SADA dose escalation phase, in which patients will receive one treatment&#xD;
      cycle.&#xD;
&#xD;
      Part B is a 177Lu-DOTA dose escalation phase, in which patients will receive up to 2&#xD;
      treatment cycles .&#xD;
&#xD;
      Part C is a repeated dosing phase where the doses determined in Part A and B will be&#xD;
      administered. Patients will receive repeated treatment cycles with a maximum of 5 cycles.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">May 2022</start_date>
  <completion_date type="Anticipated">January 2025</completion_date>
  <primary_completion_date type="Anticipated">March 2024</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>Phase 1 dose-escalation single-arm, open-label, non-randomized, multi-center trial</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To determine optimal, safe GD2-SADA protein dose</measure>
    <time_frame>6 weeks</time_frame>
    <description>Number of DLTs</description>
  </primary_outcome>
  <primary_outcome>
    <measure>To determine maximum tolerable activity of 177Lu-DOTA</measure>
    <time_frame>6 weeks</time_frame>
    <description>Number of DLTs</description>
  </primary_outcome>
  <primary_outcome>
    <measure>To assess cumulative toxicity signals following repeated dosing</measure>
    <time_frame>52 weeks</time_frame>
    <description>Number and severity of adverse events</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>SCLC</condition>
  <condition>Malignant Melanoma</condition>
  <condition>Sarcoma</condition>
  <arm_group>
    <arm_group_label>GD2-SADA:177Lu-DOTA Complex</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>GD2-SADA IV. infusion followed by 177Lu-DOTA IV. infusion (The IMP is a two-step radioimmunotherapy, delivered as two separate products GD2-SADA and 177Lu-DOTA ).&#xD;
1 treatment cycle in Part A, 2 treatment cycles in Part B and up to 5 treatment cycles in Part C</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>GD2-SADA:177Lu-DOTA Complex</intervention_name>
    <description>The IMP is a two-step radioimmunotherapy, delivered as two separate products GD2-SADA and 177Lu-DOTA, both will be administered as an IV infusion</description>
    <arm_group_label>GD2-SADA:177Lu-DOTA Complex</arm_group_label>
    <other_name>two-step radioimmunotherapy</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Signed informed consent from patient, legal guardian(s) and/or adolescents obtained in&#xD;
             accordance with local regulations. Pediatric patients must provide assent as required&#xD;
             by local regulations.&#xD;
&#xD;
          -  Age ≥18 years at the time of informed consent, for sarcoma age ≥16 years of age at&#xD;
             time of informed consent/assent&#xD;
&#xD;
          -  Measurable disease according to RECIST 1.1&#xD;
&#xD;
          -  ECOG performance status 0-1&#xD;
&#xD;
          -  Expected survival &gt;3 months&#xD;
&#xD;
          -  Platelet counts ≥100,000 cells/mm3&#xD;
&#xD;
          -  Hemoglobin ≥9 g/dL&#xD;
&#xD;
          -  Adequate renal function with serum creatinine ≤1.5 mg/dL or creatinine clearance&#xD;
             ≥60mL/min as calculated using the Cockcroft-Gault equation&#xD;
&#xD;
          -  Patient willing and able to comply with the trial protocol&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Systemic chemotherapy, radiotherapy, immunotherapy, or major surgery administered&#xD;
             within 3 weeks prior to the first planned dosing of the IMP per protocol&#xD;
&#xD;
          -  Patients receiving any other investigational therapy for their cancer within 3 weeks&#xD;
             prior to the first planned dosing of the IMP per protocol&#xD;
&#xD;
          -  Ongoing radiation toxicities from prior RT therapy&#xD;
&#xD;
          -  Patients with a diagnosis of autoimmune diseases or immunodeficiencies or documented&#xD;
             infection with human immunodeficiency virus (HIV) or hepatitis B or C virus (active)&#xD;
&#xD;
          -  Prior treatment with anti-GD2 antibody&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>16 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Taofeek K Owonikoko, MD/PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>UPMC Hillman Cancer Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Joris Wilms</last_name>
    <phone>+4570261414</phone>
    <email>clinicaltrials@ymabs.com</email>
  </overall_contact>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>November 11, 2021</study_first_submitted>
  <study_first_submitted_qc>November 11, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">November 23, 2021</study_first_posted>
  <last_update_submitted>November 11, 2021</last_update_submitted>
  <last_update_submitted_qc>November 11, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 23, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Melanoma</mesh_term>
    <mesh_term>Sarcoma</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

